Halozyme Therapeutics, Inc.
HALO
Health Care
2
exclusion reasons
1 theme
Halozyme Therapeutics, Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Halozyme Therapeutics is a biopharmaceutical company whose core business model requires animal testing for regulatory approval. The company develops enzyme-based drug delivery platforms and proprietary therapeutics, which are subject to mandatory preclinical safety testing on animals by global health authorities like the FDA and EMA. This reliance on animal models is inherent to its product development pipeline.
Cruelty Free Investing identifies Halozyme as a company that conducts pre-clinical studies of its drugs on animals. The company’s regulatory filings acknowledge that drug promotion and marketing are strictly regulated and require animal safety data. The commercial development and approval of its pharmaceutical products are contingent on this testing.
Halozyme Therapeutics is a biotechnology company that develops and commercializes novel oncology therapies and drug delivery technologies. Its proprietary enzyme platform is used to enhance the subcutaneous delivery of biologic drugs. The company’s drug development pipeline and regulatory submissions inherently require animal testing as part of preclinical safety and efficacy studies. This is confirmed by its active registration with the USDA Animal and Plant Health Inspection Service (registration number 93-R-0519), which is required for facilities conducting animal research.
Published research on Halozyme-sponsored drug candidates, such as studies on recombinant human hyaluronidase, explicitly detail the use of animal models, including Yucatan miniature pigs, to evaluate drug distribution and injection performance. The company’s own regulatory filings acknowledge that health authorities may require animal testing for product approvals. As a biopharmaceutical company advancing disruptive therapeutic solutions, animal testing remains an integral and ongoing component of its research and development activities.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.